December 21, 2018

Awny Farajallah, MD, FACP
Vice President, Head US Medical
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrence, NJ, 08648
609-302-3927; awny.farajallah@bms.com

NCCN Guidelines® Panel: Cancer-Associated Venous Thromboembolic Disease Panel

Dear Panel Members,

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed clinical data for ELIQUIS® (apixaban) to the NCCN® Cancer-Associated Venous Thromboembolic Disease Panel for your consideration. This data has been published in the New England Journal of Medicine on December 4, 2018. This study evaluated the efficacy and safety of apixaban for thromboprophylaxis in ambulatory patients with cancer who were at intermediate-to-high risk for venous thromboembolism and were initiating chemotherapy.

FDA Clearance of ELIQUIS® (apixaban):
- To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ³
- For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ³
- For the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.³

The use of apixaban for thromboprophylaxis in ambulatory patients with cancer is considered investigational.

Rationale: These data are being submitted in response to a standing request from NCCN® for new data.

As part of this submission, the following resources are included for your review.


Thank you for your consideration.

Sincerely,

Awny Farajallah, MD, FACP
Vice President, Head US Medical
Bristol-Myers Squibb Company